Please use this identifier to cite or link to this item:
https://hdl.handle.net/11147/2726
Title: | Combination of Fludarabine and Imatinib Induces Apoptosis Synergistically Through Loss of Mitochondrial Membrane Potential and Increases in Caspase-3 Enzyme Activity in Human K562 Chronic Myleloid Leukemia Cells | Authors: | Baran, Yusuf Öztekin, Coşkun Başsoy, Esen Yonca |
Keywords: | Apoptosis BCR/ABL Chronic myeloid leukemia Fludarabine Imatinib |
Publisher: | Informa Healthcare | Source: | Baran, Y., Öztekin, C., and Başsoy, E. Y. (2010). Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells. Cancer Investigation, 28(6), 623-628. doi:10.3109/07357901003631056 | Abstract: | In this study, we aimed to show the synergistic apoptotic effects of imatinib/fludarabine combination in human K562 chronic myleloid leukemia (CML) cells. There was a significant increase in cytotoxicity of combination of imatinib and fludarabine as compared to any agent alone. On the other hand, combination of both agents induced apoptosis significantly as confirmed by increases in caspase-3 enzyme activity and decreases in mitochondrial membrane potential. As a summary, the results of this study strongly suggest that combination of imatinib and fludarabine induced cell death synergistically comparing to only imatinib or fludarabine in human K562 CML cells. Copyright © 2010 Informa Healthcare USA, Inc. | URI: | http://doi.org/10.3109/07357901003631056 http://hdl.handle.net/11147/2726 |
ISSN: | 0735-7907 |
Appears in Collections: | Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.